raloxifene hydrochloride has been researched along with Triple Negative Breast Neoplasms in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Rosengren, RJ; Taurin, S | 1 |
| Bahman, F; Greish, K; Nehoff, H; Pritchard, T; Taurin, S | 1 |
| Allen, KM; Rosengren, RJ; Scandlyn, MJ; Taurin, S | 1 |
3 other study(ies) available for raloxifene hydrochloride and Triple Negative Breast Neoplasms
| Article | Year |
|---|---|
Raloxifene potentiates the effect of gefitinib in triple-negative breast cancer cell lines.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Endothelial Cells; Gefitinib; Humans; Protein Kinase Inhibitors; Quinazolines; Raloxifene Hydrochloride; Triple Negative Breast Neoplasms | 2022 |
Raloxifene nano-micelles effect on triple-negative breast cancer is mediated through estrogen receptor-β and epidermal growth factor receptor.
Topics: Animals; Cell Line, Tumor; ErbB Receptors; Estrogen Receptor beta; Estrogens; Female; Human Umbilical Vein Endothelial Cells; Humans; Maleates; Mice, SCID; Micelles; Nanoparticles; Raloxifene Hydrochloride; Random Allocation; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2019 |
Raloxifene reduces triple-negative breast cancer tumor growth and decreases EGFR expression.
Topics: Animals; Apoptosis; Carcinogenesis; Cell Movement; ErbB Receptors; Gene Expression Regulation, Neoplastic; Humans; Mice; Neoplasm Invasiveness; Raloxifene Hydrochloride; Receptors, Estrogen; Triple Negative Breast Neoplasms | 2013 |